A Phase 2 registrational study of Annamycin
Latest Information Update: 13 May 2024
At a glance
- Drugs Naxtarubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
Most Recent Events
- 07 May 2024 According to a Moleculin Biotech media release, the company continue to progress preparations for an End of Phase 2 meeting with FDA and believe following this meeting company will be in a position to commence a pivotal registration study as a 2nd line therapy in AML early next year
- 25 Mar 2024 According to a Moleculin Biotech media release, the company is preparing for an End of Phase 2 meeting with FDA and believe following this meeting we will be in a position to commence a pivotal registration study as a 2nd line therapy in AML before year end.
- 17 Dec 2020 According to a Moleculin Biotech media release, this investigator-funded clinical trial is expected to begin in 2021.